Logo image of CBIO

CRESCENT BIOPHARMA INC (CBIO) Stock Price, Quote, News and Overview

NASDAQ:CBIO - Nasdaq - US38000Q1022 - Common Stock - Currency: USD

13.21  -0.13 (-0.97%)

CBIO Quote, Performance and Key Statistics

CRESCENT BIOPHARMA INC

NASDAQ:CBIO (7/21/2025, 9:52:08 AM)

13.21

-0.13 (-0.97%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap183.49M
Shares13.89M
Float13.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO01-10 2014-01-10


CBIO short term performance overview.The bars show the price performance of CBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

CBIO long term performance overview.The bars show the price performance of CBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of CBIO is 13.21 USD. In the past month the price decreased by -8.76%.

CRESCENT BIOPHARMA INC / CBIO Daily stock chart

CBIO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.34 332.70B
AMGN AMGEN INC 14.17 158.16B
GILD GILEAD SCIENCES INC 14.01 134.87B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.01B
REGN REGENERON PHARMACEUTICALS 12.37 59.17B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 41.96B
ARGX ARGENX SE - ADR 98.06 34.43B
ONC BEONE MEDICINES LTD-ADR 7.41 31.37B
BNTX BIONTECH SE-ADR N/A 26.48B
SMMT SUMMIT THERAPEUTICS INC N/A 19.90B
INSM INSMED INC N/A 19.42B
NTRA NATERA INC N/A 19.38B

About CBIO

Company Profile

CBIO logo image Crescent Biopharma Inc (Pre-Reincorporation) is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The firm is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Company Info

CRESCENT BIOPHARMA INC

9708 Medical Center Drive

Rockville MARYLAND 94080 US

CEO: Nassim Usman

Employees: 4

CBIO Company Website

CBIO Investor Relations

Phone: 12402431201

CRESCENT BIOPHARMA INC / CBIO FAQ

What is the stock price of CRESCENT BIOPHARMA INC today?

The current stock price of CBIO is 13.21 USD. The price decreased by -0.97% in the last trading session.


What is the ticker symbol for CRESCENT BIOPHARMA INC stock?

The exchange symbol of CRESCENT BIOPHARMA INC is CBIO and it is listed on the Nasdaq exchange.


On which exchange is CBIO stock listed?

CBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CRESCENT BIOPHARMA INC stock?

10 analysts have analysed CBIO and the average price target is 26.18 USD. This implies a price increase of 98.18% is expected in the next year compared to the current price of 13.21. Check the CRESCENT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CRESCENT BIOPHARMA INC worth?

CRESCENT BIOPHARMA INC (CBIO) has a market capitalization of 183.49M USD. This makes CBIO a Micro Cap stock.


How many employees does CRESCENT BIOPHARMA INC have?

CRESCENT BIOPHARMA INC (CBIO) currently has 4 employees.


What are the support and resistance levels for CRESCENT BIOPHARMA INC (CBIO) stock?

CRESCENT BIOPHARMA INC (CBIO) has a resistance level at 13.35. Check the full technical report for a detailed analysis of CBIO support and resistance levels.


Should I buy CRESCENT BIOPHARMA INC (CBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CRESCENT BIOPHARMA INC (CBIO) stock pay dividends?

CBIO does not pay a dividend.


When does CRESCENT BIOPHARMA INC (CBIO) report earnings?

CRESCENT BIOPHARMA INC (CBIO) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of CRESCENT BIOPHARMA INC (CBIO)?

CRESCENT BIOPHARMA INC (CBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).


CBIO Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to CBIO.


Chartmill TA Rating
Chartmill Setup Rating

CBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CBIO. CBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CBIO Financial Highlights

Over the last trailing twelve months CBIO reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 34.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -341.52%
ROE -712.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-2252.94%
Sales Q2Q%N/A
EPS 1Y (TTM)34.09%
Revenue 1Y (TTM)-87.5%

CBIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to CBIO. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners47.7%
Ins Owners1.41%
Short Float %N/A
Short Ratio0.63
Analysts
Analysts84
Price Target26.18 (98.18%)
EPS Next Y-6.84%
Revenue Next YearN/A